Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 145.72
EXAS's Cash to Debt is ranked higher than
75% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. EXAS: 145.72 )
EXAS' s 10-Year Cash to Debt Range
Min: 12.24   Max: No Debt
Current: 145.72

F-Score: 2
Z-Score: 67.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3390.62
EXAS's Operating margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. EXAS: -3390.62 )
EXAS' s 10-Year Operating margin (%) Range
Min: -51374.51   Max: 1150.29
Current: -3390.62

-51374.51
1150.29
Net-margin (%) -3372.36
EXAS's Net-margin (%) is ranked higher than
53% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. EXAS: -3372.36 )
EXAS' s 10-Year Net-margin (%) Range
Min: -46049.02   Max: 1123.53
Current: -3372.36

-46049.02
1123.53
ROE (%) -46.38
EXAS's ROE (%) is ranked higher than
69% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. EXAS: -46.38 )
EXAS' s 10-Year ROE (%) Range
Min: -505.37   Max: -26.92
Current: -46.38

-505.37
-26.92
ROA (%) -43.05
EXAS's ROA (%) is ranked higher than
66% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. EXAS: -43.05 )
EXAS' s 10-Year ROA (%) Range
Min: -95.07   Max: -18.9
Current: -43.05

-95.07
-18.9
ROC (Joel Greenblatt) (%) -584.33
EXAS's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. EXAS: -584.33 )
EXAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3463.3   Max: -641.7
Current: -584.33

-3463.3
-641.7
Revenue Growth (3Y)(%) -22.70
EXAS's Revenue Growth (3Y)(%) is ranked higher than
66% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. EXAS: -22.70 )
EXAS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 47.4
Current: -22.7

0
47.4
EBITDA Growth (3Y)(%) 33.80
EXAS's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. EXAS: 33.80 )
EXAS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -39.4   Max: 45.4
Current: 33.8

-39.4
45.4
EPS Growth (3Y)(%) 33.50
EXAS's EPS Growth (3Y)(%) is ranked higher than
94% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. EXAS: 33.50 )
EXAS' s 10-Year EPS Growth (3Y)(%) Range
Min: -43.1   Max: 46.5
Current: 33.5

-43.1
46.5
» EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

EXAS Guru Trades in Q1 2014

George Soros 200,000 sh (New)
Paul Tudor Jones 11,040 sh (New)
» More
Q2 2014

EXAS Guru Trades in Q2 2014

PRIMECAP Management 2,491,300 sh (New)
Chase Coleman 2,000,000 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
Paul Tudor Jones Sold Out
George Soros Sold Out
» More
Q3 2014

EXAS Guru Trades in Q3 2014

Paul Tudor Jones 18,511 sh (New)
Steven Cohen 468,200 sh (New)
PRIMECAP Management 2,496,300 sh (+0.2%)
Chase Coleman Sold Out
» More
Q4 2014

EXAS Guru Trades in Q4 2014

Steven Cohen 2,482,400 sh (+430.2%)
PRIMECAP Management 2,521,300 sh (+1%)
Paul Tudor Jones 9,500 sh (-48.68%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 New Buy0.05%$11.17 - $17.27 $ 22.4764%2491300
George Soros 2014-06-30 Sold Out 0.03%$11.17 - $17.27 $ 22.4764%0
George Soros 2014-03-31 New Buy0.03%$11.75 - $14.82 $ 22.4767%200000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - Jun 20, 2014

Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc. Read more...
Meridian Funds Comments on Exact Sciences Corp
Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value. Read more...

Ratios

vs
industry
vs
history
P/B 8.40
EXAS's P/B is ranked higher than
72% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. EXAS: 8.40 )
EXAS' s 10-Year P/B Range
Min: 1.49   Max: 37
Current: 8.4

1.49
37
P/S 2175.00
EXAS's P/S is ranked higher than
65% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. EXAS: 2175.00 )
EXAS' s 10-Year P/S Range
Min: 8.84   Max: 2916
Current: 2175

8.84
2916
EV-to-EBIT -20.98
EXAS's EV-to-EBIT is ranked higher than
50% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EXAS: -20.98 )
EXAS' s 10-Year EV-to-EBIT Range
Min: -32.7   Max: -0.2
Current: -20.98

-32.7
-0.2
Current Ratio 12.91
EXAS's Current Ratio is ranked higher than
91% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. EXAS: 12.91 )
EXAS' s 10-Year Current Ratio Range
Min: 1.02   Max: 50.84
Current: 12.91

1.02
50.84
Quick Ratio 12.75
EXAS's Quick Ratio is ranked higher than
91% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. EXAS: 12.75 )
EXAS' s 10-Year Quick Ratio Range
Min: 1.02   Max: 50.84
Current: 12.75

1.02
50.84
Days Inventory 214.81
EXAS's Days Inventory is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. EXAS: 214.81 )
EXAS' s 10-Year Days Inventory Range
Min: 0   Max: 0
Current: 214.81

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.77
EXAS's Price/Net Cash is ranked higher than
84% of the 1357 Companies
in the Global Biotechnology industry.

( Industry Median: 56.66 vs. EXAS: 9.77 )
EXAS' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 90
Current: 9.77

2.02
90
Price/Net Current Asset Value 9.68
EXAS's Price/Net Current Asset Value is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. EXAS: 9.68 )
EXAS' s 10-Year Price/Net Current Asset Value Range
Min: 2.02   Max: 90
Current: 9.68

2.02
90
Price/Tangible Book 8.68
EXAS's Price/Tangible Book is ranked higher than
78% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. EXAS: 8.68 )
EXAS' s 10-Year Price/Tangible Book Range
Min: 1.88   Max: 34.23
Current: 8.68

1.88
34.23
Price/Median PS Value 52.26
EXAS's Price/Median PS Value is ranked higher than
67% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. EXAS: 52.26 )
EXAS' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 45.07
Current: 52.26

0.25
45.07
Earnings Yield (Greenblatt) -4.80
EXAS's Earnings Yield (Greenblatt) is ranked higher than
75% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. EXAS: -4.80 )
EXAS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -4.9   Max: 0
Current: -4.8

-4.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. As of December 31, 2013, Company owned 10 issued patents and 28 pending patent applications in the United States, and 62 issued patents and 26 pending patent applications in foreign jurisdictions. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Why I'm Short Exact Sciences - Whitney Tilson Presentation Feb 24 2015 
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Tal Oct 15 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 


More From Other Websites
EXACT SCIENCES CORP Files SEC form 10-K, Annual Report Feb 27 2015
Exact Sciences Grants Inducement Restricted Stock Unit Awards to New Employees Feb 27 2015
Biotech Stock Mailbag: Receptos, Celldex Therapeutics, Exact Sciences Feb 27 2015
Exact Sciences to Participate in Cowen and Company 35th Annual Health Care Conference Feb 25 2015
Wedbush Securities Reiterates Neutral, Lowers Price Target On EXACT Sciences On 4Q14 Recap Feb 25 2015
Exact Sciences reports 4Q loss Feb 24 2015
Exact Sciences reports 4Q loss Feb 24 2015
Exact Sciences (EXAS) Falls: Stock Goes Down 5.6% - Tale of the Tape Feb 24 2015
Exact Sciences Reports Fourth-Quarter and Full-Year 2014 Financial Results Feb 24 2015
Q4 2014 Exact Sciences Corp Earnings Release - Before Market Open Feb 24 2015
WEDC Tax Credits to Support Exact Sciences’ Growth in Wisconsin Feb 23 2015
Kase Fund's Top 10 Stocks In 2015 Feb 23 2015
Exact Sciences CEO Kevin Conroy & Lt. Gov. Rebecca Kleefisch to Make Major Economic Development... Feb 20 2015
Wedbush Securities Expects In-Line 4Q14 Results For EXACT Sciences Feb 18 2015
Exact Sciences to host fourth-quarter 2014 results webcast and call Feb 16 2015
My long, profitable relationship with Exact Sciences Feb 13 2015
Exact Sciences Names Michael S. Wygza to its Board of Directors Feb 11 2015
EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal Officers Feb 10 2015
Your first trade for Monday Feb 06 2015
Fast Money Final Trade: EEM, SCHW, TLT & EXAS Feb 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK